Clinical Trial Overview

This Phase 2 trial is sponsored by the U.S. National Cancer Institute (NCI) and was initiated in August 2017. The study evaluates the combination of the standard chemotherapy agents carboplatin and paclitaxel with the immune checkpoint inhibitor atezolizumab to reduce tumor burden prior to surgery. Enrollment is now closed, and the trial status is listed as ACTIVE_NOT_RECRUITING.

Rationale for Immune Checkpoint Inhibitor Combination

Atezolizumab is an immune checkpoint inhibitor that facilitates the recognition of cancer cells by immune cells in the tumor microenvironment. Checkpoint inhibition can remodel the tumor microenvironment and potentially synergize with chemotherapy. Consequently, the strategy aims to eradicate residual disease that may not be fully controlled by chemotherapy alone.

Differentiation from Current Standard of Care

Triple‑negative breast cancer (TNBC) lacks hormone receptors and HER2 expression, limiting targeted therapy options. The current standard of care is neoadjuvant chemotherapy, typically a carboplatin‑paclitaxel regimen. This trial adds immunotherapy to the chemotherapy backbone with the expectation of greater tumor reduction and a smaller surgical field.

Potential Impact if Successful

If the addition of atezolizumab markedly improves tumor response rates, the treatment paradigm for TNBC could shift from chemotherapy‑centric to a chemo‑immunotherapy combination approach. This would likely stimulate increased investment by pharmaceutical and biotech companies in immune‑oncology development and expand the neoadjuvant market. Patients could benefit from more conservative surgeries and improved long‑term survival.